[PRACTICE NOTE] Pharma’s Consumer Grade Imperative: Closing the Symmetry Gap

The Next Chapter of Commercial Excellence in Pharma: The Rise of Customer Excellence

Pharmaceutical science has reached levels of mastery that would have seemed unimaginable a generation ago. Clinical trials are designed to the molecular level, manufacturing systems operate with near perfect precision, and regulatory execution reflects a discipline that rivals aerospace engineering. Inside the enterprise, excellence is measurable, audited, and relentlessly refined.

Yet when those same organizations turn outward, toward the healthcare professionals who carry their innovations into the real world, the discipline begins to fracture. The lived experience of healthcare professionals is often clunky, fragmented, and misaligned with the elegance of the science it represents. The tempo of engagement follows company cadence rather than customer clarity.

This imbalance is what I call the Symmetry Gap: world-class rigor inside the lab and factory, paired with uneven, often uninspiring interactions in the marketplace. The result is a commercial system where the excellence of the science is undermined by the inconsistency of the experience.

Science, no matter how extraordinary, cannot rise to its full potential if the experience that delivers it is broken.

The Rise of Experiential Commerce

To understand why this matters, it helps to look outside healthcare. Over the past two decades, entire industries have moved from transactional efficiency to experiential mastery. Retail, travel, entertainment, financial services, and even transportation have rewritten the rules of value creation through what can be called Experiential Commerce, a model where the experience itself becomes a unit of value.

In this world, the product is no longer the primary differentiator. The differentiator is the designed system of interactions, emotions, and signals that surround it. Starbucks transformed a simple coffee purchase into a daily ritual of identity and belonging. Emirates turned air travel into an orchestrated act of care where service anticipates needs rather than reacting to them. Nike built a universe in which performance, data, and community reinforce a sense of personal possibility. Disney takes storytelling and converts it into an immersive memory that families carry for decades. Apple uses design to make complexity disappear so that confidence replaces confusion.

These companies did more than deliver goods and services. They created experiences that became economic assets in their own right. The journey became as valuable as the outcome. Customers were no longer simply buying what these brands made; they were buying how these brands made them feel, how they simplified life, and how they signaled respect.

Experiential Commerce is, at its core, the recognition that value now lives in experience as much as in product. It is measured not only in what is produced but in how it is perceived, remembered, and shared. That shift in where value resides has quietly reset expectations for every customer in every sector, including healthcare.

HCPs as Humans in Their Other Life

Healthcare professionals live in two worlds that constantly inform one another. In one, they are clinicians, scientists, and decision makers navigating guidelines, safety data, and complex care pathways. In the other, they are human beings moving through environments that have been carefully designed to remove friction and reward attention.

They stream a series on Netflix that is perfectly queued to their taste. They order groceries through Instacart and watch in real time as it moves from store to doorstep. They check in for a long haul flight with Singapore Airlines in a few intuitive clicks and arrive at an airport experience that feels orchestrated rather than chaotic. They stay in hotels that remember their preferences, from room location to pillow type. They shop through digital wallets that make payment invisible, yet secure.

These experiences do not sit in a separate mental drawer labeled “personal life.” They become the reference standard for what ease, personalization, and respect feel like. When these same individuals step into their roles as healthcare professionals, they bring those expectations with them. They may not articulate it, but they feel it when an experience with a pharmaceutical company falls short of that standard.

IQVIA data puts shape to that intuition. Across many markets, healthcare professionals report meaningfully higher advocacy and satisfaction for face-to-face interactions compared to digital channels. That pattern is not simply a preference for in-person contact. It is a signal that the quality and consistency of digital experiences are not yet meeting a reliable standard. In other words, pharma has built channels, but not yet a dependable experience.

The Consumer-Grade Imperative exists because healthcare professionals no longer benchmark pharma solely against peer companies. They benchmark it against the best experiences they encounter anywhere in their life.

Matching Pharma’s Three Standards of Excellence

At the heart of the Consumer Grade Imperative lies a simple but transformative idea. The evidentiary standards of science, the precision standard of manufacturing, and the trustworthiness standards of pharma brands must now be matched with an equally defined and elevated experiential standard.

The evidentiary standard of science demands proof. Molecules are tested, outcomes are quantified, and variability is interrogated until it is understood. Pharma manufacturing operates at a precision standard measured in microns and micrograms, where even the smallest variation can determine the difference between efficacy and risk. The trust standard of the brand demands integrity. Statements must align with behavior, transparency must accompany risk, and reputation must be guarded as a strategic asset.

The experiential standard demands coherence. It asks whether the way an organization shows up in the lives of healthcare professionals reflects the same precision, care, and respect that it applies in the lab. It asks whether the experience feels reliable, human, and thoughtfully designed across all channels.

When the experience that carries the science falls below the rigor of the science itself, the imbalance silently erodes confidence. The healthcare professional may trust the molecule but begin to question the company. They may respect the clinical evidence but grow weary of the friction that surrounds every interaction. In an industry where trust is the ultimate currency, experience has become one of its most visible proofs.

Matching these three standards does more than close a conceptual gap. It restores symmetry. It ensures that every touchpoint, from a digital portal to a field visit, is part of the same commitment to excellence. Experience stops being an afterthought and becomes one of the primary ways excellence is perceived.

No Free Passes: Why the Imperative Binds Every Function

The Consumer-Grade Imperative applies everywhere in the enterprise. It does not belong only to marketing, nor can it be confined to a dedicated customer experience team. It governs the totality of the healthcare professional’s lived journey with the company.

Marketing campaigns do not receive a free pass. They must feel as relevant and adaptive as the platforms that curate content in real time for each viewer. Sales engagements do not receive a free pass. They must be as prepared, efficient, and respectful of time as the best service encounters in any industry. Medical interactions do not receive a free pass. They must bring the same clarity, transparency, and balance that define the most trusted advisory relationships. Access and support programs do not receive a free pass. They must feel as seamless and dependable as the logistics networks customers now take for granted.

The customer does not separate these touchpoints by function. To the healthcare professional, there is one company, one brand, one set of promises, and one lived reality. Every function contributes to a single narrative of credibility, reliability, and respect.

Meeting the Consumer-Grade Imperative means applying the same discipline that governs science to the design of experience. It requires defining what good looks like, measuring it, and improving it over time. It means treating experiences as phenomena that can be designed, tested, and validated, not as random byproducts of individual effort. Only when experience is viewed as a system of quality assurance, on par with compliance or manufacturing, will the full potential of the science reach the market.

The Scale of the Intersection

The importance of this shift becomes clear when you consider the sheer volume of interactions that pharma generates in a year. Imagine the number of field representatives across a global portfolio, multiplied by the calls, visits, and details they conduct each week. Add medical science liaison interactions, congress encounters, advisory boards, webinars, lunch and learns, remote details, emails, and self service portal visits. Then extend that across brands, therapy areas, and markets.

The result is not thousands of interactions but millions of intersections every year between healthcare professionals and the enterprise. Each of those intersections is a lived expression of the brand. Each one either reinforces the belief that this company is easy to work with, respectful of time, and aligned with the realities of care, or it quietly suggests the opposite.

IQVIA’s observation that advocacy drops when interactions move from in-person to digital is a warning signal. It suggests that as the volume of digital touchpoints grows, variability in quality is also growing. In the language of quality systems, this is not a minor deviation. It is a systemic pattern.

When every interaction is a unit of value in Experiential Commerce, variability is not just a nuisance. It is a risk to trust, a drag on preference, and ultimately a constraint on the impact of the science.

Why It Matters Now

Every fragmented interaction adds friction, increases cost, and weakens preference. Every broken journey delays access and adherence. Every generic engagement risks reducing extraordinary science to ordinary noise. In a world where healthcare professionals are overloaded with information and choice, experience is no longer a veneer. It is the filter through which science is received.

Closing the Symmetry Gap is not a cosmetic exercise. It is a structural transformation. The future of commercial excellence will belong to the companies that unite the evidentiary standard of science, the trust standard of brand, and the experiential standard of engagement into one coherent system.

Those companies will treat experiences with the same seriousness as evidence. They will recognize that in Experiential Commerce, every interaction is a unit of value, a micro proof of what the organization believes about its customers. They will understand that helping healthcare professionals help patients is not just a noble aspiration but a practical design brief for every channel, every journey, and every role.

Pharma does not have a trust, messaging or engagement problem. It has a symmetry problem. Solving it is the most significant growth opportunity of its time, and the surest way to ensure that world class science achieves world class impact in the lives of patients.

Five Takeaways: Closing the Symmetry Gap

1. Experience Has Become a Unit of Value. In Experiential Commerce, value is no longer defined only by the product or molecule but by the quality of the experiences that surround it. Every interaction between a healthcare professional and the company is a micro-proof of value—each one capable of earning trust or eroding it.

2. The Three Standards of Excellence Must Now Move as One. The evidentiary standard of science and the trustworthiness standard of pharma brands must be matched by an equally defined and measurable experiential standard. Only when all three operate in harmony does the full power of the science translate into customer confidence and patient impact.

3. HCPs Bring Their Consumer Lives to Work. Healthcare professionals are not only clinicians; they are also consumers shaped by the intuitive, seamless systems of the modern world. They benchmark pharma’s engagement against the best experiences they encounter anywhere, not against industry peers. Meeting those expectations is now table stakes for credibility.

4. Every Function Owns the Experience. Marketing, sales, medical, and access do not operate in isolation from the customer’s point of view. The Consumer Grade Imperative binds them all. To the HCP, there is only one company and one brand. Every function is accountable for coherence, respect, and trust across every channel and moment.

5. Symmetry Is the Next Frontier of Commercial Excellence. Pharma’s greatest opportunity lies in closing the gap between the precision of its science and the variability of its customer experience. When belief, behavior, and system align, science earns permission, experience earns preference, and the enterprise earns the right to lead in a consumer-grade world.

About

Wayne Simmons is the author of The Customer Excellence Enterprise. He is a global customer excellence and customer experience leader, a former Inc. 500 founder and CEO, and a founding faculty member of North America’s first master’s degree program in Customer Experience Management at Michigan State University. His work focuses on helping pharmaceutical and life sciences organizations embed customer-centricity, experience delivery, and commercial excellence into how their businesses actually operate. This article is part of Wayne’s ongoing Customer Excellence Insights series, exploring how brand, experience, and commercial strategy must evolve in the age of AI, Experiential Commerce, and rising consumer-grade expectations. For deeper perspective on customer-centric transformation, experience-led growth, and the future of marketing and CX, you can also follow his newsletter, TheCustomer-Centric Marketer.

< Older Post

Newer Post >

[PRACTICE NOTE] The Next Chapter of Commercial Excellence in Pharma

By Wayne Simmons • March 15, 2026

Why Customer Excellence is emerging as the discipline that turns scientific innovation into real-world impact. Pharmaceutical science has never been stronger. Pipelines are more diverse, clinical development more precise, and manufacturing more advanced than at any point in history. Yet amid this extraordinary progress the industry faces a defining paradox. Scientific excellence has accelerated dramatically, while the experiences through which that science reaches physicians and patients have not kept pace. The next chapter of commercial excellence will not be won by companies that merely communicate their science more efficiently. It will belong to organizations that deliver it more meaningfully. The companies that lead the next era of healthcare will treat customer experience with the same rigor as clinical efficacy, ensuring that every engagement becomes living proof of their science, their purpose, and their credibility. For decades the pharmaceutical industry has set the evidentiary standard for science and the trust standard for its brands. What now emerges as the next frontier is an experiential standard capable of matching both. Only when the experience of engaging with a company reflects the same precision, credibility, and consistency that govern its science will the full value of innovation reach the people it is intended to serve. This evolution begins with Customer Excellence , the discipline that unites marketing, sales, and launch excellence into a coherent commercial operating system capable of earning both permission and preference. From Science as Foundation to Experience as Fulfillment Science remains the foundation and heartbeat of the pharmaceutical enterprise. It drives the Path-to-Prescribe, where evidence, education, and clinical outcomes shape physician confidence and influence treatment decisions. Yet even the most extraordinary science cannot fulfill its promise unless it moves successfully through the broader system that surrounds the prescribing moment. Once a therapy is recommended, the journey continues through the Path-to-Fulfill , where access, affordability, operational coordination, and patient readiness determine whether a prescription ultimately becomes therapy in the patient’s hands. Across this journey, friction, administrative burden, and fragmented processes frequently erode impact and delay treatment initiation. Sustained outcomes then depend on the Path-to-Adhere , where patient support, education, monitoring, and continuity of care determine whether individuals remain on therapy long enough to realize its intended clinical benefit. The therapeutic value created in the laboratory is only fully realized when patients are able to begin treatment and stay on it with confidence. Clinical innovation can demonstrate efficacy, but experience determines whether that efficacy becomes reality. The journey from lab to life depends on what occurs before, during, and long after the moment of prescription. Before prescribing, healthcare professionals form impressions of credibility, clarity, and relevance. At the point of decision, trust and confidence influence uptake. Afterward, access, patient readiness, and ongoing support sustain adherence and belief in the therapy. In some therapeutic areas, as many as half of prescriptions go unfulfilled or therapies discontinued prematurely. This is rarely a failure of science. It is more often a failure of system design, where burden-heavy and friction-heavy journeys make it difficult for healthcare professionals to initiate and sustain therapy for their patients. Pharma has long set the benchmark for scientific evidence and brand trust. What is now required is an experiential standard equal to those same heights, ensuring that engagement with the company feels as credible, coherent, and confidence-inspiring as the science itself. Science drives the Path to Prescribe. Experience shapes the Path to Fulfill. Sustained engagement enables the Path to Adhere. Together, these journeys define the new frontier of Customer Excellence. Why Transformation Is No Longer Enough Transformation has become the default response to nearly every commercial challenge. Digital transformation, omnichannel transformation, and now AI transformation have each promised to close the gap between companies and their customers. Yet despite billions invested across platforms, data systems, and engagement technologies, the experiences delivered to healthcare professionals often remain inconsistent, impersonal, and disconnected. The issue is not intent but orientation. Transformation modernizes tools, yet rarely challenges the mental models that define success. Organizations become more efficient at executing familiar patterns rather than reimagining how value should be delivered.Pharma does not require another transformation initiative. What it requires is a disciplined reinvention that questions the orthodoxy of activity metrics, channel proliferation, and functional isolation while restoring coherence and humanity to how the industry delivers its science to the world. Customer Excellence as a Rebellion Customer Excellence represents that shift. It is a disciplined and systemic redefinition of how value is created, delivered, and sustained. Rather than measuring progress through scale and speed alone, it positions coherence, trust, and ease as the true measures of commercial excellence. This shift is not a rebellion against compliance but against complacency. It challenges leaders to move beyond optimization toward orchestration, building organizations where the quality of engagement reflects the quality of the science itself. The Seven Shifts Defining the Discipline The seven shifts form the architecture of Customer Excellence, uniting marketing, sales, and launch excellence into a single human-centered model for sustainable growth. Shift 1. From Tangible to Intangible Value Exchange Customers increasingly evaluate companies through intangible dimensions such as trust, relevance, and ease. Experiential Commerce has elevated these factors from soft considerations to structural drivers of enterprise value. Shift 2. From Campaign-Centric to Customer-Centric Journeys Marketing can no longer rely on episodic campaigns alone. Value is created across continuous journeys where engagement extends far beyond the initial promotional moment. Shift 3. Experience as a Third Pillar of Value Product and brand may attract attention, but experience determines whether relationships endure. Organizations that integrate experience alongside product and brand create a far more resilient value proposition. Shift 4. From Transactions to Relationships Customer health must be measured over time. Longitudinal relationships built on trust ultimately drive sustainable commercial performance. Shift 5. From Funnel to Flywheel Growth no longer ends at conversion. Customer Excellence transforms disconnected interactions into a compounding cycle of engagement, trust, and expansion. Shift 6. From Neutral Interactions to Brand-Defining Moments Every interaction communicates brand character. Thoughtfully designed experiences become evidence of reliability and partnership. Shift 7. From Vertical Silos to Horizontal Journeys Customers experience companies horizontally across journeys, not vertically through internal functions. Customer Excellence realigns organizations to reflect this reality. From Rebellion to System The seven shifts describe how pharmaceutical organizations can close the gap between scientific mastery and the lived experiences that bring that science to life across the full continuum of care. Customer Excellence does not replace Marketing Excellence, Sales Excellence, or Launch Excellence . It integrates them. Together these disciplines form a unified, customer-aligned commercial operating system capable of translating scientific promise into real-world clinical and commercial impact. Within this system, marketing shapes the scientific narrative that informs the Path to Prescribe. Sales brings that narrative to life through trusted engagement with healthcare professionals. Launch orchestrates the critical moments that accelerate adoption. Customer Excellence ensures that the experience surrounding the therapy enables succes s across the Path to Fulfill and the Path to Adhere, where access, support, and sustained engagement determine whether therapeutic value is ultimately realized. This is the next chapter of commercial excellence in pharma. It moves the industry beyond transformation toward orchestration, beyond scale toward coherence, and beyond message toward meaning. Science drives the Path to Prescribe. Experience shapes the Path to Fulfill. Sustained engagement enables the Path to Adhere. Customer Excellence unites all three. Science earns permission. Experience sustains belief. Customer Excellence earns both. Key Takeaways The future of differentiation in healthcare is experiential. Scientific innovation remains essential, but the experiences surrounding therapies increasingly determine whether that innovation achieves its intended impact. Customer Excellence represents the structural response to this shift. By integrating marketing, sales, launch excellence, and service functions into a coherent operating system, organizations can translate scientific value into lived value. Trust is no longer assumed simply because a therapy demonstrates clinical efficacy. It is built through the design, coherence, and consistency of the experiences that surround prescribing, access, and patient support. Transformation initiatives may modernize tools, yet genuine change occurs when organizations replace compliance-driven thinking with a deeper conviction about the centrality of the customer. Science earns permission through evidence, while experience earns preference through delivery. Together they form the foundation of enduring growth in the era of Experiential Commerce. Diagnostic Questions to Consider As the commercial model evolves, leadership teams must confront several difficult questions. Are we still benchmarking our engagement against other pharma companies, or against the best experiences healthcare professionals encounter in their everyday lives? Where does friction persist across the real journeys of prescribing, access, and patient adherence, and how clearly do we understand the barriers preventing clinical intent from translating into treatment? Do our commercial systems reinforce the promise of our science and brand, or do they introduce complexity that quietly undermines them? Have our investments in digital platforms, omnichannel engagement, and artificial intelligence reduced the cognitive burden on healthcare professionals, or simply multiplied the number of touchpoints they must navigate? A re we organized around internal functions and campaigns, or around the journeys through which physicians and patients actually experience our therapies? Most importantly, are we building organizations that only aspire to be customer-centric , or enterprises that are structurally designed to deliver customer excellence? Closing Reflection The pharma and life sciences industry has mastered the science of discovery and the discipline of evidence. The next era of leadership will belong to companies that apply that same rigor to the experiences through which science reaches the world. When organizations align their commercial systems with the realities of modern customer expectations, innovation no longer struggles in the final mile between prescription and patient care. Instead it arrives with clarity, coherence, and confidence. Your breakthrough science deserves experiences worthy of it. Together, we turn customer excellence into real-world impact. About the Author Wayne Simmons is a customer excellence strategist and founder of The Customer Excellence Agency, where he partners with pharmaceutical and life sciences leaders to turn customer-centric ambition into durable commercial advantage. He previously served as Global Customer Excellence Lead within Pfizer’s Chief Marketing Organization and has held leadership roles with Bayer Pharmaceuticals and The Ritz-Carlton Leadership Center. Wayne writes The Customer-Centric Marketer newsletter and is the author of The Customer Excellence Enterprise: A Playbook for Creating Customers for Life. The Customer Excellence Agency: Advancing the Pursuit of Excellence in Service of Science.

Pharma commercial engines have reached unprecedented sophistication in generating prescribing intent

[PRACTICE NOTE] Journey Operations for Field Excellence

By Wayne Simmons • February 23, 2026

Pharma commercial engines have reached unprecedented sophistication in generating prescribing intent, yet a persistent structural gap remains between conviction and realized patient and commercial impact. The issue is not selling effectiveness.

[ABOUT] Advancing Human Health through The Pursuit of Excellence in Service of Science™

January 9, 2026

The Founding Philosophy of The Customer Excellence Agency Founded on the conviction that scientific brilliance only becomes human impact when excellence is engineered into leadership, culture, and experience delivery. This is a philosophy of rigor, responsibility, and reverence for the people science exists to serve.